Table 1.
Demographic features and clinical characteristics of patients with Behcet’s disease diagnosed with COVID-19 (comparison by hospitalization status)
| Hospitalized | Non-hospitalized | p* | |
|---|---|---|---|
| Sex (female/male†) | 7/8 (47/53) | 25/19 (57/43) | 0.70 |
| Age (years)‡ | 48.9 (10.5) | 45.4 (12.3) | 0.34 |
| Disease duration (month)‡ | 169.3 (93.9) | 185.1 (139.1) | 0.73 |
| Active disease† | 7 (58) | 14 (32) | 0.09 |
| Familial history for BD† | 3/15 (20) | 2/39 (5) | 0.24 |
| BD criteria† | |||
| ISG§ | 13 (87) | 32 (73) | 0.45 |
| ICBD|| | 14 (93) | 42 (95) | 0.72 |
| Medications† | |||
| Disease modifying | 6/15 (40) | 27/46 (59) | 0.33 |
| Cytotoxic drugs | 13/15 (87) | 22/46 (48) | < 0.02 |
| Biologic drugs | 2/15 (13) | 4/46 (9) | 0.98 |
| Corticosteroids | 15/15 (100) | 27/46 (59) | < 0.04 |
| Comorbid diseases† | 8/15 (53) | 15/44 (34) | 0.31 |
*Corrected by Yates method for chi-square test; †number (%); ‡mean (SD); §International Study Group; || International Criteria for Behcet Disease